Toboroz
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007· 2. fázis· Beijing Inno Medicine Co., Ltd.· Forrás
Contact: Matthew Budoff, MD
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
NCT06909565· 4. fázis· Duke University· Forrás
Contact: Olga Barillas
Toboroz
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· 2/3. fázis· Kardigan, Inc.· Forrás
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Contact: Cytokinetics MD
Fut, nem toboroz
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
NCT06713239· Cleerly, Inc.· Forrás
Fut, nem toboroz
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· 3. fázis· Eli Lilly and Company· Forrás
Meghívásos bevonás
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773· Aveera Medical, Inc.· Forrás
Toboroz
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418· Cleerly, Inc.· Forrás
Contact: Suvasini Lakshmanan, MD
Fut, nem toboroz
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· 3. fázis· Cytokinetics· Forrás
Fut, nem toboroz
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
COVID-19 Outcome Prediction Algorithm
NCT05471011· University of California, Los Angeles· Forrás
Toboroz
SELUTION4BTK Trial
NCT05055297· M.A. Med Alliance S.A.· Forrás
Contact: MedAlliance Clinical Team
Fut, nem toboroz
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
NCT04089358· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· 3. fázis· Actelion· Forrás
Fut, nem toboroz
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437· Bayer· Forrás
Fut, nem toboroz
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· 3. fázis· Loxo Oncology, Inc.· Forrás
Toboroz
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339· 3. fázis· Applied Therapeutics, Inc.· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
NCT03581292· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
NCT03417388· 4. fázis· Cedars-Sinai Medical Center· Forrás
Fut, nem toboroz
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· 2. fázis· Children's Oncology Group· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Forrás
Fut, nem toboroz
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· 3. fázis· Children's Oncology Group· Forrás